Clinical Trials Browser

palbociclib × 30 days × Clear all

NCT04439201 2026-03-18

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Phase 2 Active not recruiting

40 enrolled 9 charts

LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT05554367 2026-03-18

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06126276 2026-03-18

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT06390839 2026-03-17

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Phase 2 Active not recruiting

43 enrolled 10 charts

Lymphoma

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06997029 2026-03-16

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06843967 2026-03-13

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Phase 1/2 Recruiting

Liposarcoma, Liposarcoma, Myxoid

NCT02896335 2026-03-12

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Phase 2 Recruiting

Brain Neoplasms

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT02905318 2026-03-09

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT04288089 2026-02-27

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Phase 1 Active not recruiting

31 enrolled 12 charts

Breast Neoplasms

NCT07123090 2026-02-27

SPARCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT06188520 2026-02-24

CYCAD-1

Phase 1/2 Recruiting

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT04546009 2026-02-20

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT07347600 2026-02-20

reaINAVO

Breast Neoplasms